FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 532 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR New study to investigate breast cancer in ethnic minority groups July 11, 2023 Reunión anual de la ASCO de 2022: Gasto en servicios sociales... May 26, 2022 FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer June 27, 2025 ΚΑΡΚΙΝΟΣ ΩΟΘΗΚΩΝ February 7, 2019 Load more HOT NEWS After Saving Thousands of Dogs, Tragedy Strikes Famed Rescue Family Should Surgery And Radiation Be The Standard Treatment For DCIS? The... Can Using Hair Dyes or Hair Relaxers Impact Your Cancer Risk? Can’t Sleep? Tips for Coping with Insomnia
